Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Mar 5, 2020

Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company’s Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19

Mar 4, 2020

Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Mar 3, 2020

Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Jan 21, 2020

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Jan 16, 2020

Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

Dec 16, 2019

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Nov 20, 2019

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Nov 18, 2019

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Nov 15, 2019

Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

Nov 11, 2019
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn